drugset / Trial / NCT02533349

Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease

NCT02533349

Phase 3 Unknown 200 enrolled Samsung Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

Based on meta-analysis of prokinetics trials in laryngopharyngeal reflux disease (LPRD) (Glicksman et al. 2014), well designed study was performed in 4 articles. But, those studies had several problems including inclusion criteria, randomization methods, and placebo medication. They had similar results that prokinetics and proton pump inhibitor (PPI) had synergistic effect for management of LPRD. Therefore, the aim of study is to evaluate the efficacy of prokinetics as an additional medication to proton pump inhibitor by well designed randomized double blind case-control study.

Timeline

Start
2016-05
Primary completion
2016-12
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator LUCORIDALINES Unknown 30 mg
Comparator Pantoprazole Other / unclassified 40 mg